As part of broadening Emplicure's project and product development, an agreement has been signed with the Department of Materials Science at Uppsala University, Sweden.

The agreement includes advanced materials science characterization of drug formulations developed by Emplicure, as well as collaboration to develop new formulations of biological drugs (biologics).

Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for inhalation of pharmaceuticals.

Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for Amplicon's nicotine inhalation technology.

Emplicure AB (publ) is set to be granted a patent by the Japan Patent Office for inhalation of pharmaceuticals.

Emplicure AB:s (publ) årsredovisning för 2021 har offentliggjorts och finns tillgänglig på Emplicures webbplats www.emplicure.com

Emplicure's CEO Torbjörn W. Larsson will present the company on two separate occasions in March, at Aktiespararna and BioStock.

Detta är en rättelse av det PM - Kallelse till årsstämma i Emplicure AB (publ) som publicerades tidigare idag. Den tidigare kallelsen var felaktigt MAR-klassad.

Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.